Limited cutaneous systemic sclerosis

Limited Cutaneous Systemic Sclerosis (lcSSc) – Understanding the Condition

What is Limited Cutaneous Systemic Sclerosis?

Limited cutaneous systemic sclerosis (lcSSc) is a subtype of systemic sclerosis (scleroderma), an autoimmune connective tissue disease that causes fibrosis (hardening) of the skin and internal organs. In lcSSc, skin thickening is typically restricted to the hands, forearms, face, and lower legs, distinguishing it from diffuse systemic sclerosis, which affects larger areas of the body.

This condition was historically referred to as CREST syndrome, an acronym representing its key features:

Calcinosis – Calcium deposits in the skin and tissues
Raynaud’s phenomenon – Reduced blood flow causing fingers/toes to turn white or blue in cold temperatures
Esophageal dysmotility – Difficulty swallowing due to reduced esophageal movement
Sclerodactyly – Thickened, tight skin on the fingers
Telangiectasia – Dilated blood vessels appearing as red spots on the skin

Causes and Risk Factors

The exact cause of lcSSc remains unknown, but it is believed to result from a dysregulated immune system that triggers excessive collagen production. Risk factors include:

Genetic predisposition
Environmental triggers (e.g., silica exposure)
Female sex (more common in women)

Symptoms of lcSSc

Skin tightening on the fingers, hands, face, and forearms
Raynaud’s phenomenon – A common early symptom
Joint pain and stiffness
Difficulty swallowing and acid reflux (due to esophageal involvement)
Telangiectasia (tiny red blood vessel lesions on skin)
Pulmonary hypertension (in some cases, affecting lung blood vessels)

Complications

While lcSSc progresses more slowly than diffuse systemic sclerosis, it can still lead to complications, such as:

Pulmonary arterial hypertension (PAH) – A serious condition affecting blood flow to the lungs
Gastrointestinal issues – Acid reflux, slowed digestion
Calcinosis – Calcium deposits under the skin, causing pain and infection risk

Diagnosis and Testing

Diagnosis is based on clinical symptoms and antibody testing, including:

Anti-Centromere Antibodies (ACA) – Found in ~70-80% of lcSSc cases
Antinuclear Antibody (ANA) Panel
Pulmonary function tests and echocardiogram (to assess lung and heart involvement)

Treatment and Management

There is no cure, but treatment focuses on managing symptoms and preventing complications:

Medications for Raynaud’s phenomenon (calcium channel blockers, vasodilators)
Proton pump inhibitors for acid reflux
Immunosuppressants for severe cases
Physical therapy to maintain mobility

Key Takeaways

- Limited cutaneous systemic sclerosis affects mainly the skin of the hands, face, and forearms but can impact internal organs.
- It progresses more slowly than diffuse scleroderma but can lead to pulmonary hypertension and digestive issues.
- Early detection and management can improve quality of life.

If you suspect lcSSc or have a positive Anti-Centromere Antibody (ACA) test, consult a rheumatologist for further evaluation and monitoring.

Biomarkers related to this condition:

Anti-Centromere Ab by IFA (RDL)

Serum

The Anti-Centromere Antibody (ACA) test is an indirect immunofluorescence assay (IFA) used to detect autoantibodies that target centromere proteins. These antibodies are primarily associated with autoimmune connective tissue diseases, particularly li

Learn more

Limited cutaneous systemic sclerosis